Stay updated on Moderna Press Releases

Sign up to get notified when there's something new on the Moderna Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Moderna Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Moderna has made significant updates, including the appointment of Abbas Hussain to its Board of Directors and the initiation of a pivotal Phase 3 trial for its mRNA Norovirus vaccine, alongside a joint agreement with Cenra Healthcare to promote its mRNA respiratory vaccine portfolio in Taiwan.
    Difference
    6%
    Check dated 2024-10-03T04:56:58.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Moderna has received multiple approvals for its updated COVID-19 vaccines targeting new variants, including the KP.2 and JN.1 variants, and has launched a national awareness campaign to promote vaccination.
    Difference
    100%
    Check dated 2024-09-25T22:35:43.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Moderna has made significant updates, including the approval of its updated COVID-19 vaccine targeting the JN.1 variant by multiple health authorities, while several previous announcements regarding vaccine approvals and campaigns have been removed.
    Difference
    98%
    Check dated 2024-09-18T16:41:03.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The website has updated the price to $79.28 and reported significant developments regarding Moderna, including the receipt of a Drug Establishment License from Health Canada and a positive opinion from the EMA for its COVID-19 mRNA vaccine targeting the JN.1 variant.
    Difference
    5%
    Check dated 2024-09-11T07:46:28.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Moderna has received regulatory approvals for its updated COVID-19 vaccine targeting the SARS-COV-2 variant JN.1 in both the UK and Taiwan, alongside launching a national awareness campaign to promote vaccination.
    Difference
    7%
    Check dated 2024-09-04T04:53:19.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Moderna has received multiple approvals for its vaccines, including an updated COVID-19 vaccine targeting the KP.2 variant and an RSV vaccine, while the stock price has decreased from $86.94 to $78.98.
    Difference
    12%
    Check dated 2024-08-28T02:33:17.000Z thumbnail image

Stay in the know with updates to Moderna Press Releases

Enter your email address, and we'll notify you when there's something new on the Moderna Press Releases page.